Calcitonin: The Bone-Protecting Thyroid Peptide
Bone and Calcium Peptides
32 amino acids
Calcitonin is a peptide hormone secreted by thyroid C cells that directly inhibits osteoclast-mediated bone resorption. Salmon calcitonin, 40-50x more potent than human calcitonin, is FDA-approved for postmenopausal osteoporosis and Paget's disease.
Hay et al., Pharmacol Rev, 2018
Hay et al., Pharmacol Rev, 2018
View as imageCalcitonin was one of the first peptide hormones to become a drug. Discovered in 1962, approved by the FDA in 1975, and prescribed for decades as a nasal spray for osteoporosis, calcitonin is a 32-amino-acid peptide secreted by the parafollicular cells (C cells) of the thyroid gland. Its primary physiological role is to lower blood calcium by inhibiting osteoclasts, the cells that break down bone. Among the bone and calcium peptides that regulate skeletal health, calcitonin is the direct counterpart to parathyroid hormone: where PTH stimulates calcium release from bone, calcitonin prevents it.
Despite its long clinical history, calcitonin's role in modern medicine has narrowed. Newer osteoporosis drugs (bisphosphonates, denosumab, PTH analogs like teriparatide) have largely replaced it for bone density treatment. But calcitonin retains unique applications in acute hypercalcemia, Paget's disease, and post-fracture pain that keep it clinically relevant.
Key Takeaways
- Calcitonin directly inhibits osteoclasts within minutes by binding to calcitonin receptors, causing cell retraction, loss of the ruffled border, and cessation of bone resorption (Hay et al., Pharmacol Rev, 2018)
- The 5-year PROOF trial of 1,108 postmenopausal women showed 200 IU daily intranasal calcitonin reduced vertebral fracture risk by 33% (Chesnut et al., Am J Med, 2000)
- Salmon calcitonin is 40-50 times more potent than human calcitonin due to higher receptor binding affinity and longer half-life (Hay et al., 2018)
- Calcitonin provides analgesic effects independent of its bone-protective action, making it uniquely useful for acute vertebral compression fracture pain
- The calcitonin receptor is a class B GPCR that also forms complexes with receptor activity-modifying proteins (RAMPs) to create amylin receptors (Fletcher et al., Mol Pharmacol, 2021)
- Advanced delivery systems including nasal penetration enhancers are being developed to improve calcitonin bioavailability (Luo et al., J Control Release, 2024)
Biology of Calcitonin
Production and structure
Calcitonin is produced by the parafollicular C cells of the thyroid gland, which constitute approximately 0.1% of thyroid tissue. These neuroendocrine cells are embryologically distinct from the thyroid follicular cells that produce thyroid hormones; they originate from the neural crest rather than the pharyngeal endoderm.
The mature peptide is 32 amino acids with a disulfide bridge between positions 1 and 7 that creates an N-terminal ring structure essential for receptor binding. The C-terminus carries a prolinamide that is required for full biological activity. This compact structure is highly conserved across vertebrate species, though the amino acid sequence varies considerably, which is why salmon calcitonin (sCT) has different pharmacological properties than the human form.[1]
The calcitonin receptor
The calcitonin receptor (CTR) is a class B G-protein coupled receptor. When calcitonin binds, it activates Gs-coupled adenylyl cyclase signaling, increasing intracellular cAMP. Fletcher et al. (2021) characterized how the calcitonin receptor also serves as a component of amylin receptors: when CTR associates with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3), it forms distinct amylin receptor subtypes with different pharmacological profiles.[2]
This receptor sharing between calcitonin and amylin explains why some calcitonin effects overlap with amylin biology, and why dual amylin-calcitonin receptor agonists (DACRAs) are being developed as a new drug class. Cao et al. (2025) characterized the structural and dynamic features of cagrilintide binding to both calcitonin and amylin receptors, revealing the molecular basis for dual agonism.[3]
How calcitonin inhibits bone resorption
Calcitonin's effect on osteoclasts is rapid and dramatic. Within minutes of receptor activation, osteoclasts undergo a characteristic sequence: the ruffled border (the specialized membrane that dissolves bone mineral) retracts, the cell shrinks and detaches from the bone surface, motility decreases, and resorption activity ceases.[1]
This mechanism is fundamentally different from bisphosphonates (which kill osteoclasts) or denosumab (which prevents osteoclast formation). Calcitonin pauses existing osteoclasts without destroying them. When calcitonin levels decline, osteoclasts can resume normal activity. This reversibility distinguishes calcitonin from other antiresorptive therapies.
Salmon Calcitonin: Why Fish Peptides Work Better
Salmon calcitonin (sCT) is 40-50 times more potent than human calcitonin for inhibiting bone resorption. Three factors explain this difference: salmon calcitonin binds the human calcitonin receptor with higher affinity, it resists enzymatic degradation more effectively (longer half-life in circulation), and it produces a more sustained intracellular cAMP response.
Lee et al. (2021) developed high-affinity calcitonin analog fragments targeting the extracellular domains of the calcitonin receptor, building on the structural insights from salmon calcitonin to engineer peptides with optimized receptor binding.[4] Lee et al. (2024) further refined these peptide mutagenesis approaches to develop novel amylin and calcitonin receptor activators with tailored pharmacological profiles.[5]
Roberts et al. (2024) assessed the immunogenicity risk of salmon calcitonin peptide impurities, an important pharmaceutical quality consideration since the non-human origin of sCT means the immune system can generate neutralizing antibodies that reduce efficacy over time.[6] Approximately 30-60% of patients develop anti-salmon calcitonin antibodies during long-term use, though clinical significance varies.
Clinical Applications
Postmenopausal osteoporosis
Salmon calcitonin nasal spray (Miacalcin, Fortical) at 200 IU daily is FDA-approved for treating postmenopausal osteoporosis in women more than 5 years past menopause. The landmark PROOF (Prevent Recurrence of Osteoporotic Fractures) trial enrolled 1,108 postmenopausal women and showed that 200 IU daily intranasal calcitonin reduced the risk of new vertebral fractures by 33% over 5 years (Chesnut et al., American Journal of Medicine, 2000).
The PROOF trial had limitations: the 100 IU and 400 IU dose groups did not show statistically significant fracture reduction, the dropout rate was high (59%), and the study did not demonstrate reduction in hip or non-vertebral fractures. These issues, combined with the availability of bisphosphonates and denosumab with stronger anti-fracture evidence, have made calcitonin a second-line or third-line osteoporosis treatment.
Paget's disease of bone
Paget's disease, characterized by disordered bone remodeling with excessive osteoclast activity, was one of calcitonin's earliest approved indications. Injectable salmon calcitonin (100 IU daily or every other day) can reduce bone turnover markers, relieve bone pain, and normalize alkaline phosphatase levels. Calcitonin was the standard treatment before bisphosphonates became available.
Acute hypercalcemia
Calcitonin provides the most rapid reduction in blood calcium of any available treatment. Injectable salmon calcitonin (4-8 IU/kg every 6-12 hours) can lower serum calcium within 2-4 hours. This speed makes it valuable for acute hypercalcemia emergencies, even though the effect is modest (typically 1-2 mg/dL reduction) and diminishes after 48 hours due to tachyphylaxis (loss of response).
Post-fracture pain
Calcitonin has an analgesic effect on bone pain that is independent of its antiresorptive action. For acute vertebral compression fractures, intranasal calcitonin reduces pain and accelerates mobilization. The mechanism is not fully understood but may involve central nervous system endorphin release, direct effects on nerve fibers in bone, or modulation of inflammatory mediators at the fracture site. This analgesic property is unique among osteoporosis drugs and makes calcitonin particularly useful in the acute post-fracture setting.
Calcitonin as a Cancer Biomarker
Serum calcitonin is the primary biomarker for medullary thyroid carcinoma (MTC), a cancer of the thyroid C cells. Because MTC cells retain the ability to secrete calcitonin, elevated serum calcitonin levels can detect MTC before it becomes palpable, and rising calcitonin after surgery indicates recurrence or metastasis. A serum calcitonin above 100 pg/mL is highly specific for MTC. This diagnostic application is entirely separate from calcitonin's therapeutic uses.
The Calcitonin Family
Calcitonin belongs to a broader peptide family that includes calcitonin gene-related peptide (CGRP), amylin (IAPP), adrenomedullin, and intermedin/adrenomedullin 2. Hay et al. (2018) provided a comprehensive pharmacological update on this family, showing that these peptides share structural features and interact with overlapping receptor systems built from the calcitonin receptor and RAMPs.[1]
The family relationships have therapeutic implications. CGRP antagonists (erenumab, fremanezumab, galcanezumab) are blockbuster migraine drugs that target a calcitonin family receptor. Dual amylin-calcitonin receptor agonists (DACRAs) are being developed for obesity and diabetes. Larsen et al. (2022) examined whether "receptor balance matters" by comparing the efficacies of dual amylin and calcitonin receptor agonists, finding that the ratio of activity at different receptor subtypes affects metabolic outcomes.[7] Zhou et al. (2026) developed a long-acting stapled dual amylin and calcitonin receptor agonist for monotherapy, combining bone and metabolic benefits in a single peptide.[8]
Delivery Challenges and Innovations
Calcitonin is a peptide, which means oral delivery faces the standard peptide barriers: gastric acid degradation and poor intestinal absorption. The nasal spray formulation achieves approximately 3-5% bioavailability, far lower than injection but sufficient for clinical effect at the approved 200 IU dose.
Luo et al. (2024) published a comprehensive review of advanced nasal delivery approaches for insulin and calcitonin, covering absorption enhancers, mucoadhesive formulations, and nanoparticle delivery systems designed to improve bioavailability beyond the current 3-5%.[9] Keum et al. (2020) evaluated penetratin, a cell-penetrating peptide, as a non-invasive permeation enhancer for calcitonin delivery through nasal and skin routes, demonstrating improved peptide transport across epithelial barriers.[10]
An oral calcitonin formulation using absorption-enhancing technology reached Phase III trials but was not approved, illustrating the ongoing challenge of oral peptide delivery.
Limitations and Current Status
Weaker anti-fracture evidence than alternatives. Calcitonin reduces vertebral fractures but has not demonstrated reduction in hip fractures, which are more clinically consequential. Bisphosphonates, denosumab, and PTH analogs have stronger fracture data across multiple skeletal sites.
Tachyphylaxis. Prolonged calcitonin exposure causes receptor downregulation, reducing efficacy over time. This "escape" phenomenon limits long-term use and contributed to calcitonin's decline as a first-line osteoporosis therapy.
Cancer safety signal. A 2012 European Medicines Agency review identified a small increased cancer risk with long-term calcitonin use (primarily nasal spray), leading to restrictions in the EU. The FDA maintained approval with a more limited indication. This safety signal further positioned calcitonin as a short-term or second-line option.
Antibody formation. Up to 60% of patients on long-term salmon calcitonin develop antibodies, potentially reducing efficacy. This is an inherent limitation of using a non-human peptide.
Narrow modern role. In current practice, calcitonin is primarily used for acute post-fracture pain relief, short-term hypercalcemia management, and Paget's disease when bisphosphonates are contraindicated. Its role as a primary osteoporosis treatment has been largely supplanted by newer PTH analog approaches.
The Bottom Line
Calcitonin is a 32-amino-acid thyroid peptide that directly inhibits osteoclasts within minutes, making it one of the fastest-acting bone-protective agents available. Salmon calcitonin, 40-50x more potent than the human form, is FDA-approved as a nasal spray for postmenopausal osteoporosis (33% vertebral fracture reduction in the PROOF trial) and Paget's disease. While newer drugs have largely replaced it for long-term osteoporosis treatment, calcitonin retains unique value for acute hypercalcemia, post-fracture pain, and as a medullary thyroid carcinoma biomarker. Its receptor biology connects it to the broader calcitonin peptide family, including CGRP and amylin, with dual agonists under active development.